Hepacure

Company Overview

Snapshot

Founded in July 2024, Hepacure operates with 1–10 employees and has completed one funding round. The company is in the pre-seed stage, having secured funding from NGT HealthCare II in September 2024.

Business overview

Hepacure Pharma is focused on developing novel peptide therapies to address fatty liver diseases, specifically non-alcoholic fatty liver disease (NAFLD) and its advanced form, non-alcoholic steatohepatitis (NASH). The company's core technology centers on a peptide named Luji, which targets fibrosis and reactivates immune responses in the liver by modulating the Neuroligin-4 (NLGN4-Nrx1β) protein interaction. This therapy aims to prevent the progression of liver deterioration in NAFLD patients, serving the healthcare and life sciences sectors, particularly within pharmaceuticals and drug discovery and development.

Company Intelligence Q&A

When was Hepacure founded?

Hepacure was founded in July 2024.

What is Hepacure's primary focus?

Hepacure's primary focus is developing peptide therapies to target fibrosis in fatty liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

What is the key mechanism of Hepacure's therapy?

Hepacure's therapy utilizes a peptide called Luji, which blocks key proteins in the fibrosis pathway and reactivates natural killer (NK) cells to target hepatic stellate cells (HSCs), aiming to prevent fibrosis advancement by modulating the NLGN4-Nrx1β protein interaction.

What is Hepacure's product development stage?

Hepacure's product is currently in the R&D stage, focusing on preclinical studies for its Luji peptide therapy.